Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTM
Quantum Biopharma Ltd. Subordinate Voting Shares Class B — Quantum BioPharma — Investor Presentation (September 2026)
27 slides from Quantum Biopharma Ltd. Subordinate Voting Shares Class B's investor presentation, September 2026
Slide 1: Groundbreaking R&D meets world-class product development and commercialization
Groundbreaking R&D meets world-class product development and commercialization NASDAQ: QNTM Investor Presentation September 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This Presentation, together with any supplements and any other information that may be furnished to prospective investors by the Company, contains “forward looking information” and “forward looking statements” (forward looking information within the meaning of applicable s
Slide 3: Corporate Overview
Corporate Overview Quantum BioPharma is an R&D focused biopharmaceutical company led by a world-class science team dedicated to building a portfolio of innovative assets and biotech solutions, with three near-term monetization events. NASDAQ • Proprietary R&D conducted by a world-class team of medic
Slide 4: LUCID-MS: A New Chemical Entity with the potential to reverse multiple sclerosis
LUCID-MS: A New Chemical Entity (NCE) with the potential to reverse multiple sclerosis and other chronic neurological disorders With Phase 2 starting winter 2026-27 4
Slide 5: Multiple Sclerosis (MS): A Debilitating Disease with High Unmet Need
Multiple Sclerosis (MS): A Debilitating Disease with High Unmet Need • MS is characterized by demyelination: one of a group of disorders characterized by the destruction of myelin, the protective sheath that surrounds nerve fibers in the central nervous system • Myelin is essential for proper functi
Slide 6: An Expansive Market
An Expansive Market Prevalence of Multiple Sclerosis* 1 in 3,000 people around the globe Africa: ~120,000 Australia: 25,607 • Almost 1 million people in the US alone have been diagnosed with USA: 913,925 MS and 2.8 million people Asia: ~600,000 worldwide1 • Global MS market sales projected 2.8 M to
Slide 7: LUCID-MS: A Potential First-In-Class Approach to Treating Demyelinating Diseases
LUCID-MS: A Potential First-In-Class Approach to Treating Demyelinating Diseases • New Chemical Entity discovered by Dr. Kotra and team at • No suppression of immune system and no University Health Network immunomodulation • Mouse models of MS showed accelerated functional recovery, • Phase 1 Single
Slide 8: Portfolio Pipeline
Portfolio Pipeline Robust pipeline of products and assets focused on addressing significant unmet needs in brain disorders and alcohol health Formulation Regulatory Final Technology Transfer/ Market Clinical Trial Development Compliance Composition Commercialization Launch unbuzzd™ (Recreational alc
Slide 9: unbuzzd + REKVRY
unbuzzd™ + REKVRY™ Revolutionary technology for alcohol intoxication, life-changing opportunity A refreshing, science-backed beverage that helps people feel more refreshed and balanced after drinking. • Licensee Unbuzzd Wellness, has an exclusive, perpetual license for the consumer market • Quantum
Slide 10: Excessive Alcohol Use Continues to Wreak Havoc on Families and Communities
Excessive Alcohol Use Continues to Wreak Havoc on Families and Communities, Creating a Heavy Strain on Society as a Whole Binge drinking rates among adults aged 35–50 reached an all-time high in 20231 Rates of binge drinking among people ages 18 to 25 have been decreasing in the past decade, but rem
Slide 11: As Excessive Alcohol Use Persists, the Hangover Remedy Market Continues to Grow
As Excessive Alcohol Use Persists, the Hangover Remedy Market Continues to Grow Global Market Forecast (US$ Millions) $12,000 • The global hangover cure products market size was valued at US$2.05 billion $10,000 in 2022 and is expected to grow at a compound annual growth rate (CAGR) of $8,000 14.8%
Slide 12: The Days of "Waiting It Out" are Over
The Days of “Waiting It Out” are Over unbuzzd™ is the only dietary supplement product that provides relief from inebriation and accelerates alcohol metabolism, leading to reduced Breath Alcohol Concentration (BrAC) HOW IT WORKS: Ethanol Metabolizing Pathways unbuzzdTM helps accelerate the metabolism
Slide 13: unbuzzd Benefits
unbuzzd™ BENEFITS Improved Liver and Reduced Blood Alcohol Rapid Restoration Brain Function Content Restores mental alertness and Proprietary formulation of Ingredients help reduce BAC improves cognition post-alcohol extracts, vitamins, minerals faster than what the body consumption in an average of
Slide 14: Successful unbuzzd Clinical Trial Key Findings
Successful unbuzzd™ Clinical Trial Effect of a Novel Dietary Supplement, FSD-F2R6, on Alcohol Metabolism, Mental Clarity, and Hangover Symptoms After Alcohol Consumption: A Randomized, Double-Blind, Placebo-Controlled Crossover Study (NCT06505239). The trial, which investigated the effects of unbuzz
Slide 15: 360 Degree Marketing Approach
360 Degree Marketing Approach Organic Social Field Marketing Strategy Influencers/Brand Ambassadors On-Premise Marketing Digital/Paid Media DEMAND DEMAND Cross Promotions PR GENERATION FULFILLMENT Sales/Trade Promotions Brand Partnerships Trade Shows E-Commerce 15
Slide 16: In the Media
In the Media Video link will open in web browser Kevin Harrington’s unbuzzd Revolution: How This Will Change Society 16
Slide 17: Alcohol Misuse Treatment Upcoming Milestones
Alcohol Misuse Treatment Upcoming Milestones unbuzzd™ REKVRY™ • Launch with FUSION Distribution across Puerto Rico • Dietary supplement trial studying the • Launch with AATAC safety and efficacy of unbuzzd™ in • Expand e-commerce to TikTok Shop, IHerb, and other Acute Alcohol Intoxication completed
Slide 18: Deep Commercial Expertise
Deep Commercial Expertise 18
Slide 19: Award-Winning Experts Across R&D and Healthcare
Award-Winning Experts Across R&D and Healthcare Dr. Lakshmi P. Kotra, B.Pharm.(Hons), PhD • Professor of medicinal chemistry at Leslie Dan Faculty of Pharmacy, University of Toronto. • Senior Scientist at Krembil Research Institute, University Health Network, Toronto • Recipient of Julia Levy award,
Slide 20: An R&D Focused Business Model
An R&D Focused Business Model Tremendous revenue potential without the marketing cost burden QUANTUM MAINTAINS: 7% 20% 100% 100% royalty on gross equity stake in rights for all medical exclusive worldwide revenue of unbuzzd™ Unbuzzd Wellness and pharmaceutical patent rights to a New Inc., a non-list
Slide 21: Q2 2026 Financial Statements Highlights
Q2 2026 Financial Statements Highlights For the three months ended June 30, Strong improvements in cash and operating efficiency ($ in Thousands) 2026 2025 • $7.9M collected in net proceeds under the ATM agreement with Rodman and Renshaw, LLC, as Operating Expenses sales agent, during the six months
Slide 22: Executive Management and Advisors
Executive Management and Advisors Zeeshan Saeed Anthony Durkacz Founder, CEO, President, & Executive Co-Chair Founder & Executive Co-Chair • Founder and current CEO, President and Executive Co- • Director and Executive VP of First Republic Capital Chair of Quantum BioPharma Corporation • President o
Slide 23: Board of Directors
Board of Directors Dr. Eric Hoskins Adnan Bashir Director Director • Medical doctor and public health expert with 30+ years’ • 14+ years of experience in strategic management and experience in healthcare, public policy, economic operations development and international trade • General Manager for Al
Slide 24: Board Advisors
Board Advisors Kevin Harrington Gerry David Advisor Advisor • Original Shark on Shark Tank • Former CEO of Celsius Holdings, a • Launched over 1,000 products in zero-calorie fitness drink maker, 35- over 100 countries, creating over $6B in global sales fold increase in market cap, • Instrumental in
Slide 25: Summary
Summary Robust portfolio and pipeline focused on addressing significant unmet needs in brain disorders and alcohol health • LUCID MS, a potential multi-billion asset in demyelinating diseases, with an initial indication in MS, and an expedited path to market o 100% exclusive worldwide patent rights
Slide 26: Capital Markets Summary
Capital Markets Summary News Releases NASDAQ Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical QNTM Trial 8/14/26 Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Shares Outs
Slide 27: NASDAQ: QNTM quantumbiopharma.com
Company Zeeshan Saeed CEO & Executive Co-Chairman of the Board of Directors zsaeed@quantumbiopharma.com +1-833-304-0323 NASDAQ: QNTM quantumbiopharma.com
Quantum BioPharma — Investor Presentation (September 2026) on 6ix